


TRIUMF's main 500MeV cyclotron comes online for the first time!

# 1974



# BC CANCER

TRIUMF partners with the BC Cancer Agency and BC Cancer Research Centre to research pion cancer therapies.

# 1975

TRIUMF and Atomic Energy of Canada's isotope production division - currently operated by TRIUMF partner BWXT - establish a radioisotope production lab for medical use.

# 1979




BC's first positron emission tomography lab, used to create images of the brain for research and diagnosis, is built at UBC by TRIUMF scientists. Medical Isotopes are transported from TRIUMF via a 2.7-kilometre pneumatic tube!

# 1983

TRIUMF and Atomic Energy of Canada develop a new TRIUMF-designed cyclotron dedicated to medical isotopes in their radioisotope lab.

# 1987




EBCO (now Advanced Cyclotron Systems Incorporated) constructs a prototype compact TR-13 cyclotron at TRIUMF; cyclotrons based on this design are used to produce medical isotopes at hospitals around the world.

# 1989

UBC's Proton Eye Treatment Facility begins treating cancer patients with TRIUMF-provided medical isotopes.

# 1995



TRIUMF begins transporting fluorodeoxyglucose to the BC Cancer Agency for scans tracking cancer development. To minimize radioactive decay, deliveries arrive 20 minutes after leaving TRIUMF!

# 2004



A TRIUMF-led team of scientists from across Canada develops a method for producing key medical isotope technetium-99m by modifying existing cyclotrons, preventing an impending shortage.

# 2012

TRIUMF Innovations is formed from TRIUMF's Advanced Applied Physics Solutions team, strengthening TRIUMF's relationships with business partners across the physical sciences.

# 2017



TRIUMF and Canadian Nuclear Laboratories complete a successful production run of Actinium-225, a cutting-edge medical isotope known as "the rarest drug on Earth."

# 2019

TRIUMF partners with Fusion Pharmaceuticals to upgrade their Actinium-225 production infrastructure.

# 2020



TRIUMF and long-time partner BWXT Medical to create Actinium-225 for the development of new radiopharmaceutical treatments.

# 2022

The TRIUMF Innovations-led Canadian Medical Isotope Ecosystem initiative receives \$35M in funding from Innovation, Science and Economic Development Canada's Strategic Innovation Fund, setting the stage for the future of medical isotopes in Canada!

# 2023

